Floatz logo

ANTIBODY BISPECIFIC FOR ERBB2 AND ERBB3

Metastatic Breast Cancer

Merrimack Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

891 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
VITAMIN D
University of Illinois at Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

ANTIBODY BISPECIFIC FOR ERBB2 AND ERBB3 is also rated in:

Her2 Amplified Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →
HER-2 Gene AmplificationDormant
CC
Indicative ·
47 / 100
View asset →
breast neoplasmDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →